JP2018521124A - 粘膜病変の治療のための配合物 - Google Patents
粘膜病変の治療のための配合物 Download PDFInfo
- Publication number
- JP2018521124A JP2018521124A JP2018516645A JP2018516645A JP2018521124A JP 2018521124 A JP2018521124 A JP 2018521124A JP 2018516645 A JP2018516645 A JP 2018516645A JP 2018516645 A JP2018516645 A JP 2018516645A JP 2018521124 A JP2018521124 A JP 2018521124A
- Authority
- JP
- Japan
- Prior art keywords
- combination
- extract
- use according
- weight
- punica granatum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 238000011282 treatment Methods 0.000 title claims abstract description 30
- 230000009854 mucosal lesion Effects 0.000 title claims abstract description 24
- 238000009472 formulation Methods 0.000 title abstract description 17
- 239000000284 extract Substances 0.000 claims abstract description 71
- 244000294611 Punica granatum Species 0.000 claims abstract description 25
- 235000014360 Punica granatum Nutrition 0.000 claims abstract description 25
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 24
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 22
- 208000009137 Behcet syndrome Diseases 0.000 claims abstract description 17
- 230000002265 prevention Effects 0.000 claims abstract description 8
- 210000004392 genitalia Anatomy 0.000 claims abstract description 3
- 210000000214 mouth Anatomy 0.000 claims description 13
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 12
- 239000013543 active substance Substances 0.000 claims description 12
- 210000004877 mucosa Anatomy 0.000 claims description 8
- 239000008513 turmeric extract Substances 0.000 claims description 8
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 claims description 6
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 claims description 6
- 235000002780 gingerol Nutrition 0.000 claims description 6
- 210000003296 saliva Anatomy 0.000 claims description 6
- 208000007514 Herpes zoster Diseases 0.000 claims description 4
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 4
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 4
- 235000013824 polyphenols Nutrition 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 208000001688 Herpes Genitalis Diseases 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 201000004946 genital herpes Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000035935 pregnancy Effects 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 208000004898 Herpes Labialis Diseases 0.000 claims description 2
- 241000700586 Herpesviridae Species 0.000 claims description 2
- 208000029433 Herpesviridae infectious disease Diseases 0.000 claims description 2
- 206010067152 Oral herpes Diseases 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- 238000007910 systemic administration Methods 0.000 claims description 2
- 239000002676 xenobiotic agent Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 208000027496 Behcet disease Diseases 0.000 abstract description 8
- 241001529453 unidentified herpesvirus Species 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 230000003902 lesion Effects 0.000 description 8
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 102000016943 Muramidase Human genes 0.000 description 6
- 108010014251 Muramidase Proteins 0.000 description 6
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 241000234314 Zingiber Species 0.000 description 6
- 235000006886 Zingiber officinale Nutrition 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 235000008397 ginger Nutrition 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 229960000274 lysozyme Drugs 0.000 description 6
- 239000004325 lysozyme Substances 0.000 description 6
- 235000010335 lysozyme Nutrition 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 235000003392 Curcuma domestica Nutrition 0.000 description 5
- 235000013976 turmeric Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 210000003800 pharynx Anatomy 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 3
- 229920002079 Ellagic acid Polymers 0.000 description 3
- 208000009889 Herpes Simplex Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229960002852 ellagic acid Drugs 0.000 description 3
- 235000004132 ellagic acid Nutrition 0.000 description 3
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 3
- 230000003232 mucoadhesive effect Effects 0.000 description 3
- -1 nother Species 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 229940042129 topical gel Drugs 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 235000014375 Curcuma Nutrition 0.000 description 2
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 2
- 206010019973 Herpes virus infection Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010028116 Mucosal inflammation Diseases 0.000 description 2
- 201000010927 Mucositis Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 230000003602 anti-herpes Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000020708 ginger extract Nutrition 0.000 description 2
- 229940002508 ginger extract Drugs 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229940109529 pomegranate extract Drugs 0.000 description 2
- 229960001462 sodium cyclamate Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229940052016 turmeric extract Drugs 0.000 description 2
- 235000020240 turmeric extract Nutrition 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000003253 viricidal effect Effects 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- OQWKEEOHDMUXEO-UHFFFAOYSA-N (6)-shogaol Natural products CCCCCC=CC(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-UHFFFAOYSA-N 0.000 description 1
- BBMFSGOFUHEVNP-UHFFFAOYSA-N 4-hydroxy-2-methylbenzoic acid Chemical compound CC1=CC(O)=CC=C1C(O)=O BBMFSGOFUHEVNP-UHFFFAOYSA-N 0.000 description 1
- 241001116747 Aglaomorpha coronans Species 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 244000187129 Bacopa monnieria Species 0.000 description 1
- 235000015418 Bacopa monnieria Nutrition 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 244000302899 Cassia mimosoides Species 0.000 description 1
- 235000014112 Cassia mimosoides Nutrition 0.000 description 1
- 208000019736 Cranial nerve disease Diseases 0.000 description 1
- 229930153442 Curcuminoid Natural products 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 244000119298 Emblica officinalis Species 0.000 description 1
- 235000015489 Emblica officinalis Nutrition 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010061978 Genital lesion Diseases 0.000 description 1
- 206010061979 Genital pain Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 244000270834 Myristica fragrans Species 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 241001420836 Ophthalmitis Species 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 206010031009 Oral pain Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 241001247821 Ziziphus Species 0.000 description 1
- 244000158786 Ziziphus joazeiro Species 0.000 description 1
- 235000001329 Ziziphus joazeiro Nutrition 0.000 description 1
- OQWKEEOHDMUXEO-BQYQJAHWSA-N [6]-Shogaol Chemical compound CCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-BQYQJAHWSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003622 anti-hsv Effects 0.000 description 1
- 230000002019 anti-mutation Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000014826 cranial nerve neuropathy Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 208000010403 panophthalmitis Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 235000013525 pomegranate juice Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940092665 tea leaf extract Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
クルクマ・ロンガ抽出物:20mg〜100mg
ピューニカ・グラネイタム抽出物(40%エラグ酸誘導体含有):10mg〜60mg
ジンギベル・オフィキナレ抽出物(35%ギンゲロール含有):2mg〜20mg
クルクマ・ロンガ抽出物:50mg
ピューニカ・グラネイタム抽出物(40%エラグ酸誘導体含有):20mg
ジンギベル・オフィキナレ抽出物(35%ギンゲロール含有):10mg
クルクマ・ロンガアルコール抽出物(ウコン)又は他の種(other species):500mg
ピューニカ・グラネイタム抽出物40%エラグ酸誘導体:120mg
ジンギベル・オフィキナレ脂溶性抽出物:200mg
ヒドロキシエチルセルロース:3000mg
ポリソルベート80:3000mg
p−ヒドロキシ−安息香酸メチル:100mg
プロピレングリコール:100000mgまで
クルクマ・ロンガアルコール抽出物(ウコン)又は他の種(other species):50mg
ピューニカ・グラネイタム抽出物40%エラグ酸誘導体:20mg
ジンギベル・オフィキナレ脂溶性抽出物:10mg
アルギン酸ナトリウム塩:200mg
キシリトール:600mg
グリチルリチン酸アンモニウム:10mg
シクラミン酸ナトリウム:40mg
ポリソルベート80:5mg
クルクマ・ロンガアルコール抽出物(ウコン)又は他の種(other species):50mg
ピューニカ・グラネイタム抽出物40%エラグ酸誘導体:20mg
ジンギベル・オフィキナレ脂溶性抽出物35%ギンゲロール:8mg
キシリトール:430mg
ヒアルロン酸:200mg
グリチルリチン酸アンモニウム:10mg
シクラミン酸ナトリウム:40mg
ポリソルベート80:5mg
臨床研究の主な標的は以下のとおりであった:
a−口内のベーチェット病の病変の瘢痕化時間
b−兆候/症状の低減
c−ヘルペス性疾患の日数の低減
d−唾液及びリゾチーム含量の決定
口唇ヘルペスを有する6人の女性被験体(18歳〜26歳)に、実施例2に記載の配合物を投与した。錠剤を1週間にわたって1日4回投与した(口内でゆっくりと溶解させる)。さらに、患者に実施例1の局所用ゲルを投与した。ゲルを症状の解消及び正常患者状態の回復に必要な期間にわたって病変に適用した。
ベーチェット病の場合、5人の患者を実施例1のゲル配合物により2週間にわたって1日5回治療した。潰瘍サイズの減少(76%)及び疼痛の低減(46%)とともに、潰瘍数の減少(9つから3つ)が観察された。
Claims (16)
- 粘膜病変の予防及び/又は治療における使用のための、クルクマ・ロンガ、ピューニカ・グラネイタム及びジンギベル・オフィキナレの抽出物からなる活性物質の組合せであって、該クルクマ・ロンガ、ピューニカ・グラネイタム及びジンギベル・オフィキナレの抽出物がそれぞれの重量比6(±2):2(±1):1(±0.5)で存在する、組合せ。
- 粘膜病変の予防及び/又は治療における使用のための、クルクマ・ロンガ、ピューニカ・グラネイタム及びジンギベル・オフィキナレの抽出物を含む活性物質の組合せであって、該クルクマ・ロンガ、ピューニカ・グラネイタム及びジンギベル・オフィキナレの抽出物がそれぞれの重量比6(±2):2(±1):1(±0.5)で存在し、
前記抽出物が全体として全投与活性物質の50重量%超を占め、及び/又は、
前記抽出物以外の各々の考え得る活性物質が、前記クルクマ・ロンガ、ピューニカ・グラネイタム及びジンギベル・オフィキナレの抽出物のうち最低のものよりも少なくとも50重量%低い量で存在する、
組合せ。 - 前記クルクマ・ロンガ、ピューニカ・グラネイタム及びジンギベル・オフィキナレの抽出物が全体として全投与活性物質の90重量%超を占める、請求項2に記載の使用のための組合せ。
- 前記クルクマ・ロンガの抽出物がクルクミノイドを20重量%〜30重量%の量で含有し、前記ピューニカ・グラネイタムの抽出物がポリフェノールを60重量%〜95重量%の量で含有し、前記ジンギベル・オフィキナレの抽出物がギンゲロール及びショウガオールを合計して20重量%〜50重量%の量で含有する、請求項1〜3のいずれか一項に記載の使用のための組合せ。
- 20mg〜100mgのクルクマ・ロンガ抽出物と、10mg〜50mgのピューニカ・グラネイタム抽出物と、2mg〜20mgのジンギベル・オフィキナレ抽出物とを含む投与単位用量として配合される、請求項1〜4のいずれか一項に記載の使用のための組合せ。
- 医薬賦形剤が配合される、請求項1〜5のいずれか一項に記載の使用のための組合せ。
- 局所又は全身投与に好適な形態である、請求項1〜6のいずれか一項に記載の使用のための組合せ。
- 治療対象の粘膜病変が口腔、唇、咽喉及び/又は生殖器部に存在する、請求項1〜7のいずれか一項に記載の使用のための組合せ。
- 前記粘膜病変がヘルペスウイルス科感染又はベーチェット病の結果として生じる、請求項1〜8のいずれか一項に記載の使用のための組合せ。
- 前記粘膜病変が口唇ヘルペス、陰部ヘルペス、帯状ヘルペス、眼部ヘルペス、連環状ヘルペス、妊娠ヘルペスの結果として生じる、請求項9に記載の使用のための組合せ。
- 前記ヘルペスウイルス科がHSV−1、HSV−2、HHV3、HZVのうち1つ以上である、請求項9に記載の使用のための組合せ。
- 前記粘膜病変が化学療法及び/又は放射線療法の結果として生じる、請求項1〜8のいずれか一項に記載の使用のための組合せ。
- 罹患粘膜上の細菌性合併症の治療/予防に更に有用である、請求項1〜12のいずれか一項に記載の使用のための組合せ。
- 前記組合せと唾液との接触による生体異物の溶解の増進に更に有用である、請求項1〜12のいずれか一項に記載の使用のための組合せ。
- 治療に使用されるための、請求項1〜7のいずれか一項に記載の抽出物の組合せ。
- 請求項1〜7のいずれか一項に記載の抽出物の組合せを含む医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15171355.9 | 2015-06-10 | ||
EP15171355.9A EP3103465A1 (en) | 2015-06-10 | 2015-06-10 | Formulations for the treatment of mucosal lesions |
PCT/IB2016/000791 WO2016198942A1 (en) | 2015-06-10 | 2016-06-10 | Formulations for the treatment of mucosal lesions |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018521124A true JP2018521124A (ja) | 2018-08-02 |
JP6830482B2 JP6830482B2 (ja) | 2021-02-17 |
Family
ID=53385534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018516645A Active JP6830482B2 (ja) | 2015-06-10 | 2016-06-10 | 粘膜病変の治療のための配合物 |
Country Status (14)
Country | Link |
---|---|
US (1) | US10786540B2 (ja) |
EP (2) | EP3103465A1 (ja) |
JP (1) | JP6830482B2 (ja) |
KR (1) | KR20180030482A (ja) |
CN (1) | CN108012530B (ja) |
AU (1) | AU2016276144B2 (ja) |
BR (1) | BR112017026422B1 (ja) |
ES (1) | ES2728557T3 (ja) |
HU (1) | HUE045225T2 (ja) |
MX (1) | MX2017016029A (ja) |
PL (1) | PL3307292T3 (ja) |
PT (1) | PT3307292T (ja) |
TR (1) | TR201908166T4 (ja) |
WO (1) | WO2016198942A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023037299A1 (en) * | 2021-09-09 | 2023-03-16 | Integria Healthcare (Australia) Pty Limited | Anti-inflammatory compositions comprising ginger and turmeric |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008523153A (ja) * | 2004-12-14 | 2008-07-03 | ザ キグリー コーポレーション | 疾病の伝染を減少させる組成物及び方法 |
CN102670588A (zh) * | 2012-05-04 | 2012-09-19 | 中国科学院上海生命科学研究院湖州营养与健康产业创新中心 | 鞣花酸用于制备抗病毒药物的应用 |
CN103638502A (zh) * | 2013-12-12 | 2014-03-19 | 苏振华 | 一种治疗白塞病的药物及其制备方法 |
CN104524508A (zh) * | 2014-12-24 | 2015-04-22 | 赵红 | 一种治疗消化性溃疡的中药及其制备方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6596313B2 (en) | 2001-08-06 | 2003-07-22 | The Quigley Corporation | Nutritional supplement and methods of using it |
MXPA05001051A (es) * | 2002-08-06 | 2005-04-08 | The Quigley Corp | Composiciones anti-microbianas y metodos para usar las mismas. |
US7175987B2 (en) * | 2002-08-06 | 2007-02-13 | The Quigley Corporation | Compositions and methods for treatment of herpes |
US20080031979A1 (en) * | 2006-08-04 | 2008-02-07 | Claude Saliou | Use of extracts for the treatment of viral disorders |
US20090175971A1 (en) | 2008-01-08 | 2009-07-09 | Mark Dreher | Method of using composition comprising pomegranate extracts against the common cold |
DE202009002126U1 (de) * | 2009-02-13 | 2009-04-16 | Orthomol Pharmazeutische Vertriebs Gmbh | Spurenelement enthaltende Zusammensetzung |
KR101077920B1 (ko) | 2009-07-08 | 2011-10-31 | 한국생명공학연구원 | 울금 추출물을 포함하는 인플루엔자 바이러스 감염의 예방 및 치료용 조성물 및 뉴라미니데이즈 활성의 억제용 조성물 |
MY152711A (en) * | 2009-12-04 | 2014-11-28 | Colgate Palmolive Co | Oral compositions containing a combination of natural extracts and related methods |
IT1402018B1 (it) | 2010-10-11 | 2013-08-28 | Indena Spa | Formulazioni per il trattamento delle affezioni delle prime vie respiratorie. |
JP2013001666A (ja) * | 2011-06-14 | 2013-01-07 | Yasuharu Omura | 栄養剤組成物 |
CN103690709B (zh) * | 2013-12-14 | 2016-03-09 | 青岛市中心医院 | 一种治疗肠白塞病的中药 |
EP3103464A1 (en) * | 2015-06-10 | 2016-12-14 | Raman Mehta | Formulations for the treatment of disorders of the mouth, throat and respiratory tract |
-
2015
- 2015-06-10 EP EP15171355.9A patent/EP3103465A1/en not_active Withdrawn
-
2016
- 2016-06-10 HU HUE16731323A patent/HUE045225T2/hu unknown
- 2016-06-10 PL PL16731323T patent/PL3307292T3/pl unknown
- 2016-06-10 PT PT16731323T patent/PT3307292T/pt unknown
- 2016-06-10 CN CN201680032972.6A patent/CN108012530B/zh active Active
- 2016-06-10 WO PCT/IB2016/000791 patent/WO2016198942A1/en active Application Filing
- 2016-06-10 BR BR112017026422-6A patent/BR112017026422B1/pt active IP Right Grant
- 2016-06-10 KR KR1020177037809A patent/KR20180030482A/ko not_active Application Discontinuation
- 2016-06-10 US US15/735,391 patent/US10786540B2/en active Active
- 2016-06-10 EP EP16731323.8A patent/EP3307292B1/en active Active
- 2016-06-10 JP JP2018516645A patent/JP6830482B2/ja active Active
- 2016-06-10 ES ES16731323T patent/ES2728557T3/es active Active
- 2016-06-10 TR TR2019/08166T patent/TR201908166T4/tr unknown
- 2016-06-10 MX MX2017016029A patent/MX2017016029A/es unknown
- 2016-06-10 AU AU2016276144A patent/AU2016276144B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008523153A (ja) * | 2004-12-14 | 2008-07-03 | ザ キグリー コーポレーション | 疾病の伝染を減少させる組成物及び方法 |
CN102670588A (zh) * | 2012-05-04 | 2012-09-19 | 中国科学院上海生命科学研究院湖州营养与健康产业创新中心 | 鞣花酸用于制备抗病毒药物的应用 |
CN103638502A (zh) * | 2013-12-12 | 2014-03-19 | 苏振华 | 一种治疗白塞病的药物及其制备方法 |
CN104524508A (zh) * | 2014-12-24 | 2015-04-22 | 赵红 | 一种治疗消化性溃疡的中药及其制备方法 |
Non-Patent Citations (2)
Title |
---|
BORHANI HAGHIGHI A, BAGHERI M: "Pomegranate Juice May Be a Potential Addition to anti-Beh?et Armamentarium: A Hypothesis", CLINICAL RHEUMATOLOGY, vol. 26, no. 10, JPN6020006546, 4 April 2007 (2007-04-04), pages 1709 - 1710, XP019520862, ISSN: 0004219492, DOI: 10.1007/s10067-007-0608-z * |
JADHAV P ET AL.: "Antiviral Potential of Selected Indian Medicinal (Ayurvedic) Plants Against Herpes Simplex Virus 1 a", NORTH AMERICAN JOURNAL OF MEDICAL SCIENCES, vol. 4, no. 12, JPN6020006544, December 2012 (2012-12-01), pages 641 - 647, ISSN: 0004219491 * |
Also Published As
Publication number | Publication date |
---|---|
CN108012530A (zh) | 2018-05-08 |
HUE045225T2 (hu) | 2019-12-30 |
PL3307292T3 (pl) | 2020-01-31 |
AU2016276144A1 (en) | 2017-12-21 |
EP3103465A1 (en) | 2016-12-14 |
MX2017016029A (es) | 2018-04-13 |
CN108012530B (zh) | 2021-07-02 |
WO2016198942A1 (en) | 2016-12-15 |
US20180104301A1 (en) | 2018-04-19 |
US10786540B2 (en) | 2020-09-29 |
JP6830482B2 (ja) | 2021-02-17 |
TR201908166T4 (tr) | 2019-06-21 |
BR112017026422B1 (pt) | 2021-10-05 |
EP3307292A1 (en) | 2018-04-18 |
AU2016276144B2 (en) | 2022-01-13 |
PT3307292T (pt) | 2019-05-31 |
BR112017026422A2 (pt) | 2018-08-21 |
ES2728557T3 (es) | 2019-10-25 |
EP3307292B1 (en) | 2019-03-13 |
KR20180030482A (ko) | 2018-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6966998B2 (ja) | 口腔、咽喉及び気道の障害の治療のための配合物 | |
US20100278936A1 (en) | Composition for treating skin lesions | |
US20110064826A1 (en) | Composition for treating skin lesions | |
CA2783612A1 (en) | Composition for treating skin lesions | |
JP6830482B2 (ja) | 粘膜病変の治療のための配合物 | |
CN1750819A (zh) | 治疗或预防病毒感染的方法 | |
US20210308071A1 (en) | Treatment method to abort and or reduce the severity of upper respiratory viral illness as well as to prevent upper respiratory viral illness in humans | |
BE1019216A3 (nl) | Kleefpleister voor de toediening van therapeutische agentia. | |
CN109276594A (zh) | 一种用于治疗蛇串疮的中药组合物及其制备方法 | |
CN115803040B (zh) | 用于处理covid-19和相关病症的组合物 | |
US20230310612A1 (en) | Anti-viral composition and method for preparing the same | |
AU2009217410A1 (en) | Composition for treating skin lesions | |
US20110229584A1 (en) | Compound for the control of herpes simplex virus using glycyrrhizic acid, lipoic acid, allantoin, and slippery elm | |
WO2011124493A1 (de) | Zusammensetzung enthaltend bestandteile aus sonnenhut, holunder und kamille zur behandlung von erkältungskrankheiten | |
WO2022096705A1 (en) | Radiation-induced fibrosis treatment | |
CA2997992A1 (en) | Herbal composition for the prevention and treatment of urinary infections | |
DE212011100015U1 (de) | Zusammensetzung zur Behandlung von Reizhusten und/oder Halsschmerzen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20180115 |
|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20180518 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180518 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190415 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200225 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200221 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200521 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200727 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210105 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210126 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6830482 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |